Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03591731
Title Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Intergroupe Francophone de Cancerologie Thoracique

lung large cell carcinoma

neuroendocrine carcinoma



Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries FRA

Additional content available in CKB BOOST